PROGEN

PROGEN is a long-established, privately-held German biotech firm that has evolved from a diagnostics and antibodies company into a key supplier of analytical tools for the gene therapy sector. Its core business revolves around providing essential reagents and assays, particularly for AAV vector characterization and quality control, serving academic, biotech, and pharmaceutical clients worldwide. The company leverages its decades of expertise in antibody manufacturing and its ISO 13485 certification to offer reliable, off-the-shelf products supported by scientific expertise. PROGEN operates as a critical enabler in the gene therapy supply chain, focusing on tools for titer determination, empty/full capsid analysis, and immunogenicity testing.

Platform for AAV (adeno-associated virus) analytical tools, including ELISA kits for titer and immunogenicity, monoclonal/polyclonal antibodies against various AAV serotypes and proteins, reference standards, and density gradient media for purification. Also expanding into lentiviral and LNP analytical tools.

PROGEN competes in the life science tools and reagents market, facing competition from large conglomerates like Thermo Fisher Scientific, Sartorius, and Charles River Laboratories, which offer broad portfolios. It differentiates through deep specialization in AAV analytics, high-quality antibodies, ISO 13485 certification, and direct scientific support from a focused team.